Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07147517 · ClinicalTrials.gov registry record

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

A clinical trial of COVID-19 and RSV, sponsored by University of California, San Diego.

Recruiting
Registry status
25,000
Enrollment target
2
Study locations

NCT07147517 is a study of COVID-19 and RSV that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 25,000 participants, below the 55,091-participant average among 203 other COVID-19 trials with a reported enrollment target (55% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07147517, a study of COVID-19 and RSV, is actively recruiting participants, sponsored by University of California, San Diego.

RECRUITING
Registry status
25,000 participants
Enrollment target
2
Study locations

Study Summary

The CHARM network will be established through three primary institutions-Beth Israel Deaconess Medical Center (BIDMC), the University of California San Diego (UCSD), and the University of Washington (UW)-along with their subcontracting institutions. At UCSD and partner sites, the CHARM network will be implemented via the PREVENT project. All PREVENT participants will be consented in to Component A0 (Community Testing) and a subset of A0 participants will be invited to participate and will be consented into the other components: Component A (Ongoing Testing); Component A Sub-study (Immunology); Component B (Household Transmission). Component A0 participants (Community testing) will be members of the community who are interested in accessing testing for respiratory infections and will be asked to provide limited information that will then be used for screening for study Components A and/or B. Participants in Component A (Ongoing Testing ) will undergo weekly symptom screening. If they report symptoms, they will be asked to provide a nasal swab and complete illness questionnaires on the day they report symptoms (Day 0) and again on Days 7 and 14. Participants in Component A Sub-study (Immunology) will provide blood and saliva/nasal fluid samples twice a year, as well as before and after infection and/or immunization against priority pathogens. Participants in Component B (Household Transmission) will complete daily symptom questionnaires and nasal swabs for 14 days following enrollment, regardless of symptoms. Those who are symptomatic at enrollment will also complete retrospective daily diaries from symptom onset to the enrollment date. Additionally, they provide blood and/or saliva/nasal fluid samples at enrollment and again 28 days later. For all Components, UCSD will provide PCR test results for SARS-CoV-2, Influenza A/B, and RSV for nasal swab samples.

Interventions

  • OTHER Component A0
  • OTHER Component A1
  • OTHER Component A2
  • OTHER Component B

Study Locations (2)

California

  • UC San Diego - La Jolla
  • San Ysidro Health - San Ysidro

Trial Details

FieldValue
Enrollment Target 25,000 participants
Start Date 2025-10-08
Est. Completion 2030-10-30

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT07147517

The ClinicalTrials.gov registry entry for NCT07147517 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,091-participant average among 203 other COVID-19 trials with a reported enrollment target (55% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 4 interventions - of which Component A0 is the first listed.

NCT07147517 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07147517 about?

NCT07147517 is a clinical study titled "Preparedness Through Respiratory Virus Epidemiology and Community Engagement". The CHARM network will be established through three primary institutions-Beth Israel Deaconess Medical Center (BIDMC), the University of California San Diego (UCSD), and the University of Washington (UW)-along with their subcontracting institutions. At UCSD and partner sites, the CHARM network will ...

What is the current status of trial NCT07147517?

This trial is currently recruiting. The enrollment target is 25,000 participants. The study started on 2025-10-08. Estimated completion is 2030-10-30.

What conditions does trial NCT07147517 study?

This clinical trial studies the following conditions: COVID-19, RSV, FLU, Respiratory Infection Virus.

What interventions are being tested in trial NCT07147517?

The interventions under investigation include: Component A0 (OTHER), Component A1 (OTHER), Component A2 (OTHER), Component B (OTHER).

Who is sponsoring clinical trial NCT07147517?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07147517 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.